Squarepoint
ABUS icon

Squarepoint’s Arbutus Biopharma ABUS Stock Holding History

Squarepoint’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,000
Closed -$87.3K – 4421
2025
Q1 		$87.3K Buy
+25,000
New +$83.4K ﹤0.01% 4255
2024
Q4 		– Sell
-1,270,000
Closed -$4.89M – 4966
2024
Q3 		$4.89M Sell
1,270,000
-175,000
-12% -$671K 0.01% 1436
2024
Q2 		$4.47M Hold
1,445,000
– – 0.01% 1454
2024
Q1 		$3.73M Buy
+1,445,000
New +$3.74M 0.01% 1663

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint's ABUS Position: Q1 2026 in Review

Squarepoint sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 28,775 shares — an estimated $138K sold.

Squarepoint first reported a position in ABUS in Q4 2016 and held it in 16 quarters. The position peaked at $586K in Q2 2020. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Squarepoint reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 28,775 Arbutus Biopharma shares in Q1 2026, an estimated $138K.
  • Squarepoint first reported a position in Arbutus Biopharma in Q4 2016 and held it in 16 quarters.
  • Squarepoint's Arbutus Biopharma position peaked at $586K in Q2 2020.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.